Menu
Back to Journals » OncoTargets and Therapy » Volume 6
Primary primitive neuroectodermal tumor of the cervix
Authors Li B, Ouyang L, Han X, Zhou Y, Xin Tong, Zhang Z, Zhang Z, han Y, Qiu X
Received 28 March 2013
Accepted for publication 7 May 2013
Published 17 June 2013 Volume 2013:6 Pages 707—711
DOI https://doi.org/10.2147/OTT.S45889
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Bo Li,1 Ling Ouyang,1 Xue Han,1 Yang Zhou,1 Xin Tong,1 Shulang Zhang,1 Qingfu Zhang2
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, 2Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, People’s Republic of China
Abstract: Primary primitive neuroectodermal tumors (PNETs) are rare and high-grade malignant tumors that mostly occur in children and young adults. The most common sites are the trunk, limbs, and retroperitoneum. Herein, we present a case of a PNET involving the cervix uteri in a 27-year-old woman. The lesion showed characteristic histologic features of a PNET and was positive for the immunohistochemical markers cluster of differentiation (CD) 99, vimentin, neuron-specific enolase, neural cell adhesion molecule 1 (CD56), and CD117 (c-kit), further defining the tumor while helping to confirm PNET. The clinical Stage IIIB tumor was treated with chemotherapy and radiotherapy.
Keywords: primitive neuroectodermal tumor, PNET, cervical neoplasm, immunohistochemistry
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.